No Data
Essence Pharmaceuticals: Report for the third quarter of 2024
jinghua pharmaceutical group (002349.SZ) released its performance for the first three quarters, with a net income of 0.164 billion yuan, a year-on-year decrease of 15.93%.
jinghua pharmaceutical group (002349.SZ) released the quarterly report for the third quarter of 2024. In the first three quarters, the company achieved revenue...
We Think Jinghua Pharmaceutical Group (SZSE:002349) Can Manage Its Debt With Ease
Jinghua Pharmaceutical Plans to Divest Entire 18.6% Stake in Jinsili Pharmaceutical
jinghua pharmaceutical group (002349.SZ): plans to sell the remaining equity of its joint venture subsidiary Jin Si Li Pharmaceutical Industry for 48 million yuan.
GeLonghui October 10th | Jinghua Pharmaceutical Group (002349.SZ) announced that the company plans to sell 18.6% of the shares of Jiangsu Jinsili Pharmaceutical Co., Ltd. (referred to as "Jinsili Pharmaceutical" or "trading symbol") through the National SME share transfer system, with a transaction amount of approximately 48 million yuan. After the transaction is completed, Jinghua Pharmaceutical Group will no longer hold equity in Jinsili Pharmaceutical.
jinghua pharmaceutical group (002349.SZ): The company and its subsidiaries are currently not engaging in CXO related business.
The Jinghua Pharmaceutical Group (002349.SZ) stated on the investor interaction platform on September 30 that the company and its subsidiaries are currently not engaged in CXO-related business.
No Data
No Data